Progestins used in hormonal replacement therapy display different effects in coronary arteries from New Zealand white rabbits

Maturitas

Volumn 49, Issue 4, 2004, Pages 304-314

  Pedersen, Nina G ^a   Pedersen, Susan H ^a   Dalsgaard, Tórur ^a   Lund, Claus O ^a   Nilas, Lisbeth ^a   Ottesen, Bent ^b  

^a HVIDOVRE HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Cardiovascular disease; Coronary arteries; Hormonal replacement treatment; New Zealand white rabbits; Progestins

Indexed keywords

ACETYLCHOLINE; CALCIUM; ENDOTHELIN 1; ESTER DERIVATIVE; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NITROPRUSSIDE SODIUM; PLACEBO;

ARTICLE; ATHEROSCLEROSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY; DIET; FEMALE; HORMONE SUBSTITUTION; MUSCLE CONTRACTILITY; NEW ZEALAND; NONHUMAN; OVARIECTOMY; RABBIT; RECORDING; VASOCONSTRICTION;

ACETYLCHOLINE; ANIMALS; ARTERIES; CALCIUM; CORONARY VESSELS; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; MEDROXYPROGESTERONE 17-ACETATE; MENOPAUSE; NG-NITROARGININE METHYL ESTER; NITROPRUSSIDE; NORETHINDRONE; OVARIECTOMY; POTASSIUM; PROGESTINS; RABBITS; VASOCONSTRICTION; VASODILATION;

ANIMALIA; EQUIDAE; ORYCTOLAGUS CUNICULUS;

EID: 8644286383     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2004.02.007     Document Type: Article

References (33)

1. Schenck-Gustafsson K. Risk factors for cardiovascular disease in women: assessment and management. Eur. Heart J. 17(Suppl. D):1996;2-8
2. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post menopausal women. JAMA. 280:1998;605-613
3. Grady D., Herrington D., Vittner V., Blumenthal R., Davidson M., Hlatky M., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA. 288:2002;49-57
4. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M., et al. Risk and benefits of estrogen plus progestin in healthy postmenopausal women, principal results from the women's health initiative randomized controlled trial. JAMA. 288:2002;321-333
5. Bush T.L., Barret Conner E., Cowan L.D. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from lipid research clinics program follow up study. Circulation. 75:1987;1102-1109
6. Hunt K., Vessey M., Mc Pherson K., Coleman M. Long-term surveillance mortality and cancer incidence in women receiving hormone replacement therapy. Br. J. Obstet. Gynaecol. 94:1987;620-635
7. Paganini-Hill A., Toss R., Henderson B.E. Postmenopausal oestrogen treatment and stroke: a prospective study. Br. Med. J. 297:1989;519-522
8. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med. 20:1991;47-63
9. Grodstein F., Samfer M.J., Colditz G.A., Willet W.C., Manson J.E., Joffe M., et al. Postmenopausal hormone replacement therapy and mortality. N. Engl. J. Med. 336:1997;1769-1775
10. Sarrel P.M. The differential effects of oestrogens and progestins on vascular tone. Hum. Reprod. Update. 5:1999;205-209
11. Adams M.R., Register T.C., Golden D.L., Wagner D., Williams J.K. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;217-221
12. Hanke H., Hanke S., Bruck B., Brehme U., Gugel N., Finking G., et al. Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis. Atherosclerosis. 121:1996;129-138
13. Thigpen J.E., Setchell K.D., Ahlmark K.B., Locklear J., Spahr T., Caviness G.F., et al. Phytoestrogen content of purified, open- and closed-formula laboratory animal diets. Lab. Anim. Sci. 5:1999;530-536
14. Mulvany M.J., Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ. Res. 41:1977;19-26
15. Mulvany M.J., Washaw D.M. The active tension-length curve of vascular smoothe muscle related to its cellular components. J. Gen. Physiol. 74:1979;85-104
16. Mulvany M.J., Aalkjaer C. Structure and function of small arteries. Physiol. Rev. 70:1990;921-961
17. Prieto D., Mulvany M.J., Nyborg N.C. (+)-S-12967 and (-)-S-12968: 1.4-dihydropyridine stereoisomers with calcium channel agonistic and antagonistic properties in rat resistance arteries. Br. J. Pharmacol. 103:1991;1703-1708
18. Corr L., Burnstock G., Poole-Wilson P. Responses of the rabbit epicardial coronary artery to acetylcholine and adrenoreceptor agonists. Cardiovasc. Res. 25(3):1991;256-262
19. Dalsgaard T., Larsen C.R., Mortensen A., Larsen J.J., Ottesen B. New animal model for the study of postmenopausal coronary and cerebral artery function the Watanabe Heritable Hyperlipidemic rabbit fed on a diet avoiding phytoestrogens. Climacteric. 5:2002;178-189
20. Masaki T., Yanagisawa M. Physiology and pharmacology of endothelins. Med. Res. Rev. 12(4):1992;391-421
21. Wingrove C.S., Stevenson J.C. 17β-Oestradiol inhibits stimulated endothelin release in human vascular endothelial cells. Eur. J. Endocrinol. 137:1997;205-808
22. Ylikorkala O., Orpana A., Puolakka J., Pyorala T., Viinikka L. Postmenopausal hormone replacement decreases plasma levels of endothelin-1. J. Clin. Endocrinol. Metab. 80:1995;3384-3387
23. Miyagawa K., Rösch J., Stanczyk F., Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat. Med. 3(3):1997;324-327
24. Minshall R.D., Stanczyk F.Z., Miyagawa K., Uchida B., Axthelm M., Novy M., et al. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys. Endocrinol. Metab. 83:1998;649-659
25. Alexandersen P., Haarbo J., Sandholt I., Shalmi M., Lawaetz H., Christiansen C. Norethidrone acetate enhances the antiatherogenic effect of 17-beta-estradiol: a secondary prevention study of atherosclerosis in ovariectomized cholesterol fed rabbits. Arterioscler. Thromb. Vasc. Biol. 18:1998;902-907
26. Jiang C., Sarrel P.M., Lindsay D.C., Poole-Wilson P.A., Collins P. Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro. Eur. J. Pharmacol. 211:1992;163-167
27. Williams J.K., Honoré E.K., Washburn S.A., Clarkson T.B. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J. Am. Coll. Cardiol. 24:1994;1757-1761
28. Clarkson T.B., Anthony M.S., Wagner J.D. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J. Clin. Endocrinol. Metab. 86(11):2001;5396-5404
29. Adams M.R., Anthony M.S., Manning J.M., Golden D.L., Parks J.S. Low-dose contraceptive estrogen-progestin and coronary artery atherosclerosis of monkeys. Obstet. Gynecol. 96(2):2000;250-255
30. Alexanderson P., Haarbo J., Zandberg P., Jespersen J., Skouby S.O., Christiansen C. Lack of difference among progestins on the antiatherogenic effect of ethinyl estradiol: a rabbit study. Hum. Reprod. 18(7):2003;1395-1403
31. Nacthtigall L.E., Nachtigall R.H., Nachtigall R.D., Beckman E.M. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet. Gynecol. 54:1979;74-79
32. Falkeborn M., Persson I., Adami H., Bergstrom R., Eaker E., Lithell H., et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br. J. Obstet. Gynaecol. 99(10):1992;821-828
33. Psaty B.M., Heckberr S.R., Atkins D., Lemaitre R., Koepsell T.D., Wahl P.W., et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch. Int. Med. 154:1994;1333-1339